Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
15.03
+0.08 (0.54%)
At close: May 13, 2026, 4:00 PM EDT
15.02
-0.01 (-0.07%)
After-hours: May 13, 2026, 4:00 PM EDT
Amarin Corporation Employees
Amarin Corporation had 80 employees as of December 31, 2025. The number of employees decreased by 195 or -70.91% compared to the previous year.
Employees
80
Change (1Y)
-195
Growth (1Y)
-70.91%
Revenue / Employee
$2,709,513
Profits / Employee
-$420,163
Market Cap
315.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 80 | -195 | -70.91% |
| Dec 31, 2024 | 275 | 0 | - |
| Dec 31, 2023 | 275 | -90 | -24.66% |
| Dec 31, 2022 | 365 | -195 | -34.82% |
| Dec 31, 2021 | 560 | -440 | -44.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| GSK plc | 66,841 |
| Bristol-Myers Squibb Company | 32,500 |
| Grifols | 25,247 |
| Organon & Co. | 10,000 |
| Biogen | 7,500 |
| Scilex Holding Company | 34 |
AMRN News
- 14 days ago - Amarin Reports 2026 First Quarter Financial Results - GlobeNewsWire
- 4 weeks ago - Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 - GlobeNewsWire
- 2 months ago - Amarin highlights new recommendation for treatment of CV risk - TheFly
- 2 months ago - Amarin to present data in patients at extreme cardiovascular risk - TheFly
- 2 months ago - Amarin highlights recent data published on REDUCE-IT study - TheFly
- 2 months ago - Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities - TheFly
- 2 months ago - Amarin issues call to action for American Heart Month - TheFly
- 2 months ago - This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease - GlobeNewsWire